Eli Lilly (LLY) market share drops to 56% in India as generics flood

AI Summary

Eli Lilly (LLY) saw its market share in India's GLP-1 weight-loss drug category decline to 56% in March from 61% in February, according to Pharmarack data. Meanwhile, Novo Nordisk (NVO) maintained a steady 25% market share despite the influx of generic semaglutide drugs following the expiration of its patent last month. The launch of 26 brands by 13 Indian generic companies is significantly impacting sales for Eli Lilly's higher-priced tirzepatide products. As generic options become more affordable, the competitive landscape for weight-loss treatment in India is changing rapidly, likely benefiting Novo Nordisk in the long run.